Stablecoin Development Corporation, formerly known as NovaBay Pharmaceuticals, Inc., reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated $2.2 million in staking revenue during the second quarter, marking its first revenue from staking activities, as it had not previously engaged in digital asset holdings. However, the company also faced a substantial unrealized loss of $50.6 million on its digital assets, primarily due to fluctuations in the market price of its core holding, SKY tokens. This resulted in a net loss from continuing operations of $41.1 million for the quarter, compared to a loss of $1.9 million in the same period last year.

In terms of operational changes, the company underwent a significant transformation, including a corporate name change and a shift in focus towards digital assets. The January 2026 Private Placement raised approximately $134 million, which included $25 million in cash and $109 million in SKY tokens and stablecoins. This capital has been pivotal in establishing the company's digital asset treasury strategy. As of June 30, 2026, Stablecoin Development held 2.29 billion SKY tokens, representing about 10% of the total supply, with a fair value of $119.2 million, accounting for approximately 94% of the company's total assets.

The company also reported a notable increase in general and administrative expenses, which rose to $5.4 million from $1.9 million year-over-year, largely due to stock-based compensation and increased costs associated with its transition to a digital asset-focused business model. Additionally, the company successfully eliminated its warrant liabilities by exercising all outstanding October 2025 Pre-Funded Warrants on a cashless basis, which simplified its capital structure and reduced future non-cash adjustments related to warrant fair value.

Looking ahead, Stablecoin Development Corporation's management believes that its existing cash and cash equivalents, along with the potential to monetize a portion of its SKY holdings, will be sufficient to meet operational needs for at least the next twelve months. The company retains access to its ATM Program, with approximately $84.5 million available for issuance, which will support future acquisitions of digital assets. However, the company acknowledges that its ability to fund growth and meet obligations will depend on market conditions and access to capital on favorable terms.

About Stablecoin Development Corp

NovaBay Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing proprietary antimicrobial products, primarily hypochlorous acid-based solutions for eye care, wound care, and dermatology. Its core offerings included Avenova eye spray and wound care products. The company operates in healthcare markets targeting consumers and medical professionals, emphasizing non-toxic, scientifically proven solutions. Currently, it is winding down operations, pursuing liquidation, or exploring strategic alternatives.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov